Friday, 14 Dec 2018

You are here

Dendrimer Nanocarrier Delivers IGF-1 to Degenerative Cartilage

Researchers from MIT have developed a novel treatment for osteoarthritis (OA) by using dendrimer-based nanocarriers to deliver insulin-like growth factor 1 (IGF-1) to chondrocytes within joint cartilage and in animal models have shown when these nanocarriers injected into rat knees in models of OA, they reduced cartilage degeneration.

Dendrimers are repetitively branched molecules containing highly symmetric, spherical compounds. In these experiments the nanocarriers allow the dendrimer–IGF-1 to penetrate and be retained by full-thickness bovine cartilage ex vivo. 

One of the challenges of delivering therapies (e.g., anabolic growth factors) to cartilage is that the tissue is that the chondrocytes reside deep within dense, anionic cartilage tissue. To overcome this biological barrier, they conjugated a IGF-1 (growth factor) to a cationic nanocarrier for targeted delivery to chondrocytes and retention within joint cartilage after direct intra-articular injection.

Amine terminal polyamidoamine (PAMAM) dendrimers were integrated with variable molar ratios of poly(ethylene glycol) (PEG) to control surface charge. Using variably PEGylated dendrimers, an optimal formulation showing 70% uptake into cartilage tissue and 100% cell viability was selected.

When conjugated to insulin-like growth factor 1 (IGF-1), the dendrimer penetrated bovine cartilage of human thickness within 2 days and enhanced therapeutic IGF-1 joint residence time in rat knees by 10-fold for up to 30 days.

Using a rat model of knee OA, a single injection of dendrimer–IGF-1 rescued cartilage and bone more effectively than free IGF-1. Dendrimer–IGF-1 reduced width of cartilage degeneration by 60% and volumetric osteophyte burden by 80% relative to untreated rats at 4 weeks after surgery.

These results suggest improve pharmacokinetics and efficacy of disease-modifying osteoarthritis drugs in the clinic.

This study shows that using that PEGylated PAMAM dendrimer nanocarriers with disease-modifying agents to target chondrocytes may be therapeutic in knee OA.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Low Risk of Serious Complications with Meniscectomy

Lancet reports on the safety of over 1 million arthroscopic partial meniscectomies done in the United Kingdom and found a low overall risk in the first 90 days. They examined Hospital Episode Statistics on  1,088,782 arthroscopic partial meniscectomies (1997-2017); 699 965 of which were eligible for analysis. They sought to identify complications occurring in the 90 days after the index procedure.

Pre-Diabetes Associated Risk for Arthritis, Obesity and Physical Inactivity

The current MMWR reports that arthritis is seen in nearly one-third of adults with prediabetes and that more than half of such patients are obese and not engaged in regular physical activity.

Doctor-diagnosed arthritis affects 54.4 million in the U.S. and the CDC expects this to rise to 78.4 million by 2040.

Controversial New Super Opioid Approved by FDA

Amidst a new DEA report demonstrating a record number of opioid overdose deaths (n-72,000 or ~ 200 deaths per day), the FDA has approved a newer and far more potent opioid than those that are currently being abused at alarming rates. The new agent is named Dsuvia.

Late Breaker: Can Tanezumab Be Revived for OA?

The monoclonal antibody tanezumab, which blocks nerve growth factor, showed significant benefits in pain and function among patients with osteoarthritis (OA) of the knee or hip, and rates of severe adverse joint events such as rapidly progressive OA that had plagued earlier studies were low, a researcher reported at the annual meeting of the American College of Rheumatology in Chicago last week.

Vitamin D Fails to Improve Bone Health

The current edition of Lancet Diabetes & Endocrinology suggests that neither vitamin D supplementation, nor dose, will improve bone density or prevent fractures in adults. (Citation source: https://buff.ly/2O9tqxI)